Search for: "OTSUKA PHARMACEUTICAL CO LTD" Results 1 - 20 of 33
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
19 Dec 2007, 4:04 pm
Singer -- In a December 17, 2007 press release, Otsuka Pharmaceutical Co., Ltd. and PDL BioPharma, Inc. announced a finalized agreement in which Otsuka acquires intellectual property related assets to IV Busulfex ® (busulfan) from PDL. [read post]
17 Nov 2010, 7:05 pm by Lawrence B. Ebert
DNJ on Monday, Nov. 15 upheld the Abilify patent of Otsuka Pharmaceutical Co. [read post]
28 Mar 2012, 1:31 am by Mark Summerfield
This time the drug in question is ‘atypical’ antipsychotic aripiprazole, marketed by Bristol-Meyers Squibb (BMS) as ABILIFY, under license from the patentee Otsuka Pharmaceutical Co., Ltd. [read post]
1 Feb 2015, 9:59 pm by Patent Docs
Otsuka Pharmaceutical Co. [read post]
15 Oct 2015, 2:35 pm by Lawrence B. Ebert
Sandoz, 678 F.3d 1280 :In summary, the district court's careful analysis exposed the Defendants' obviousness case for what it was—a poster child for impermissible hindsight reasoning. showed up the district court.The drug in question: Aripiprazole is the active ingredient in the antipsychotic drug marketed by Otsuka Pharmaceutical Co., Ltd. [read post]
15 Mar 2015, 8:48 pm by Patent Docs
Otsuka Pharmaceutical Co., Ltd. v. [read post]
26 May 2014, 9:59 pm by Patent Docs
Otsuka Pharmaceutical Co. v. [read post]
15 May 2018, 8:29 am by Jim Higgins
The District Court has ordered the defendants, Bristol-Myers Squibb Co., and Otsuka Pharmaceutical Co. [read post]
15 May 2018, 8:29 am by Jim Higgins
The District Court has ordered the defendants, Bristol-Myers Squibb Co., and Otsuka Pharmaceutical Co. [read post]
10 Jun 2012, 12:31 am by Mark Summerfield
Generic Health Pty Ltd v Otsuka Pharmaceutical Co Ltd [2012] FCA 412 (23 April 2012) Practice and procedure – interlocutory injunction – whether application for leave to appeal should be referred to a Full Court Generic Health Pty Ltd will have the opportunity to appeal the decision of a single judge of the Federal Court of Australia granting a preliminary injunction preventing it from launching a generic version of the antipsychotic drug… [read post]
7 May 2012, 10:51 am by Rantanen
By Jason Rantanen Otsuka Pharmaceutical Co., Ltd. v. [read post]
18 Mar 2014, 7:02 pm by FDABlog HPM
Karst –       It was just a little more than three months ago that we blogged on the topic of “premature notice” in the context of a Complaint filed by Otsuka Pharmaceutical Co., Ltd. [read post]
31 Aug 2017, 5:34 pm by FDABlog HPM
Court of Appeals for the District of Columbia Circuit isued a 31-page Opinion handing FDA a victory in a dispute kicked off by Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceuticals Co., Ltd. [read post]
22 May 2018, 12:20 pm by Tom Lamb
The drug companies responsible for Rexulti in the US are Otsuka Pharmaceutical Co., Ltd. [read post]
5 Jul 2015, 4:18 am by Mark Summerfield
’  I explained that Swiss-type claims are treated as if they cover any and every method of making a medicament of any kind that includes the compound as an active ingredient, and with the intention of it being used to treat the new condition.By sheer coincidence, on 29 June 2015 Justice Yates, in the Federal Court of Australia, handed down a ruling in Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4) [2015] FCA 634, in which he has… [read post]
22 May 2018, 12:20 pm by Tom Lamb
The drug companies responsible for Rexulti in the US are Otsuka Pharmaceutical Co., Ltd. [read post]
31 Jan 2015, 8:47 pm by Mark Summerfield
  The drug is marketed in Australia by Bristol-Meyers Squibb (BMS) as ABILIFY, under license from the patentee Otsuka Pharmaceutical Co., Ltd.The Full Court has upheld the earlier finding of a single judge of the court that the patent is valid, notwithstanding that there is prior art teaching which, if carried out in a particular manner, could result in the claimed product. [read post]